Zai Lab Limited - ADR

NASDAQ:ZLAB   4:00:00 PM EDT
33.84
+1.20 (+3.68%)
5:48:06 PM EDT: $33.99 +0.15 (+0.44%)
Products

Zai Lab Partner Macrogenics Announces FDA Approval Of Margenza™ For Patients With Pretreated Metastatic Her2-Positive Breast Cancer

Published: 12/17/2020 01:23 GMT
Zai Lab Limited - ADR (ZLAB) - Zai Lab Partner Macrogenics Announces FDA Approval of Margenza™ for Patients With Pretreated Metastatic Her2-positive Breast Cancer.
Product Launch in U.S. Anticipated in March 2021.